Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.

Arreola Ornelas H, Rosado Buzzo A, García L, Dorantes Aguilar J, Contreras Hernández I, Mould Quevedo JF.

Reumatol Clin. 2012 May-Jun;8(3):120-7. doi: 10.1016/j.reuma.2011.12.009. Epub 2012 Mar 3.

2.

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.

Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G.

Curr Med Res Opin. 2010 Apr;26(4):965-75. doi: 10.1185/03007991003600271.

PMID:
20178405
3.

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP.

Clin Drug Investig. 2008;28(9):583-601.

PMID:
18666805
4.

A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.

O'Connor AB, Noyes K, Holloway RG.

J Am Geriatr Soc. 2007 Aug;55(8):1176-84. Review.

PMID:
17661955
5.

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective.

Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G.

J Med Econ. 2012;15(3):481-92. doi: 10.3111/13696998.2012.660254. Epub 2012 Feb 17. Review.

PMID:
22339078
6.

Economic evaluation of oral treatments for neuropathic pain.

Cepeda MS, Farrar JT.

J Pain. 2006 Feb;7(2):119-28.

PMID:
16459277
7.

A cost-utility comparison of four first-line medications in painful diabetic neuropathy.

O'Connor AB, Noyes K, Holloway RG.

Pharmacoeconomics. 2008;26(12):1045-64. doi: 10.2165/0019053-200826120-00007.

PMID:
19014205
8.

Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.

Carlos F, Ramírez-Gámez J, Dueñas H, Galindo-Suárez RM, Ramos E.

J Med Econ. 2012;15(2):233-44. doi: 10.3111/13696998.2011.640730. Epub 2011 Dec 5.

PMID:
22082033
9.

Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.

Wielage R, Bansal M, Wilson K, Klein R, Happich M.

Spine (Phila Pa 1976). 2013 May 15;38(11):936-46. doi: 10.1097/BRS.0b013e31828264f9.

PMID:
23250234
10.

A systematic review of pharmacoeconomic studies for pregabalin.

Parker L, Huelin R, Khankhel Z, Wasiak R, Mould J.

Pain Pract. 2015 Jan;15(1):82-94. doi: 10.1111/papr.12193. Epub 2014 May 10. Review.

PMID:
24815038
11.
12.

Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.

Gore M, Sadosky AB, Zlateva G, Clauw DJ.

Pain Pract. 2009 Sep-Oct;9(5):363-74. doi: 10.1111/j.1533-2500.2009.00292.x. Epub 2009 Jun 4.

13.

Career lifetime advances and key developments: diabetes.

Baglioni P, Govindan J, Khan A.

Clin Med (Lond). 2007 Jun;7(3):303-4. No abstract available.

PMID:
17639617
14.

Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.

Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Planas-Comes A.

J Eval Clin Pract. 2012 Dec;18(6):1170-9. doi: 10.1111/j.1365-2753.2011.01752.x. Epub 2011 Aug 30.

PMID:
21883712
15.
16.
17.

Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.

Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

J Pain. 2006 Jun;7(6):399-407.

PMID:
16750796
18.

Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.

Gore M, Tai KS, Chandran A, Zlateva G, Leslie D.

J Med Econ. 2012;15(1):19-31. doi: 10.3111/13696998.2011.629262. Epub 2011 Oct 20.

PMID:
21970699
19.
20.

Fibromyalgia: poorly understood; treatments are disappointing.

[No authors listed]

Prescrire Int. 2009 Aug;18(102):169-73.

PMID:
19746561

Supplemental Content

Support Center